---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022864"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:22:09.451882+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM

## Summary
- Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.
- Cemsidomide Phase 1 MM dose escalation complete; 100 µg QD safe for expansion; ORR 50% at 100 µg, 40% at 75 µg.
- One patient achieved MRD-negative complete response after prior T-cell engager therapies.
- Will not advance CFT1946 beyond Phase 1; seeking partnership for BRAF program.
- Cash $234.7M, runway into 2027; earned $4M from two Roche preclinical milestones.

## SEC filing metadata
- accession: 0001628280-25-022864
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/0001628280-25-022864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/cccc-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022864
- JSON: https://secwatch.observer/filing/0001628280-25-022864.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.